Canada's Medexus Q4 revenue misses analyst expectations, net loss widens

Medexus Pharmaceuticals

Thu 23:16

Overview
Canada specialty pharma firm's fiscal Q4 revenue declined and missed analyst expectations
Net loss for Q4 widened to $2.68 mln from $0.55mln last year
Company attributed revenue decline to loss of Gleolan sales and Rupall generic competition

Outlook
Company expects fiscal 2027 GRAFAPEX product-level net revenue of $30 mln to $32 mln
Medexus continues to expect GRAFAPEX annual net revenue will exceed $100 mln within five years
Company expects GRAFAPEX annual Adjusted Gross Margin will ultimately be about 80%

Result Drivers
     
RUPALL GENERIC COMPETITION - Co said significant generic competition led to sharp declines in Rupall demand and revenue
GLEOLAN AGREEMENT TERMINATION - Revenue decline attributed to end of U.S. Gleolan agreement in March 2025
GRAFAPEX GROWTH - Company said GRAFAPEX posted strong quarter-over-quarter demand growth and contributed positively to adjusted EBITDA

Company press release: ID:nNFCWSLdQ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$24.65 mln
$25.59 mln (4 Analysts)
Q4 Net Loss
 
$2.68 mln
 
Q4 Adjusted EBITDA
Beat
$4.28 mln
$3.47 mln (4 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Medexus Pharmaceuticals Inc is C$6.00, about 48.5% above its June 25 closing price of C$4.04
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)